University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 6G-12-3


Open-Label Phase I/II (Safety Lead-In) Study of Trans Sodium Crocetinate (TSC) with Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy.

Type: Cancer Therapy
Phase: Phase I/II
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Chemotherapy: Systemic, Other, Radiation: External
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Naveed Wagle, M.D.
Other Trial Staff:  Cynthia Estrada, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.